Reducing skeletal complications and bone pain with intravenous ibandronate for metastatic bone disease

European Journal of Cancer, Supplement

Volumn 2, Issue 5, 2004, Pages 5-8

  Body, J J ^a  

^a JULES BORDET INSTITUTE   (Belgium)

Author keywords

Bisphosphonates; Bone pain; Breast cancer; Ibandronate; Metastatic bone disease

Indexed keywords

IBANDRONIC ACID; OPIATE AGONIST; PLACEBO;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE METASTASIS; BONE PAIN; BREAST CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SCORING SYSTEM;

EID: 2442429729     PISSN: 13596349     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejcsup.2004.01.002     Document Type: Article

References (29)

1. Body J.J. Metastatic bone disease clinical and therapeutic aspects. Bone. 13:(Suppl. 1):1992;S57-S62
2. Theriault R.L., Hortobagyi G.N. Bone metastasis in breast cancer. Anticancer Drugs. 3:1992;455-462
3. Coleman R.E. Skeletal complications of malignancy. Cancer. 80:(Suppl. 8):1997;1588-1594
4. Fulfaro F., Casuccio A., Ticozzi C., et al. The role of bisphosphonates in the treatment of painful metastatic bone disease a review of phase III trials. Pain. 78:1998;157-169
5. Lucas L.K., Lipman A.G. Recent advances in pharmacotherapy for cancer pain management. Cancer Practice. 10:(Suppl. 1):2002;S14-S20
6. Janjan N. Bone metastases approaches to management. Semin. Oncol. 28:(Suppl. 11):2001;28-34
7. Coleman R.E. Management of bone metastases. Oncologist. 5:2000;463-470
8. Fleisch H. Bisphosphonates in Bone Disease. From the Laboratory to the patient. 2nd rev. ed. 1992;Parthenon Publishing Group Inc, New York
9. Rodan G.A., Fleisch H.A. Bisphosphonates mechanisms of action. J. Clin. Invest. 97:1996;2692-2696
10. Pavlakis N., Stockler M. Bisphosphonates for breast cancer. Cochrane Database Syst. Rev. 1:2002;CD003474
11. Body J.J. Bisphosphonates in the treatment of metastatic breast cancer. J. Mammary Gland Biol. Neoplasia. 6:2001;477-485
12. Ernst D.S., MacDonald R.N., Paterson A.H.G., et al. A double-blind, crossover trial of intravenous clodronate in metastatic bone pain. J. Pain Symptom. Manage. 7:1992;4-11
13. Body J.J., Bartl R., Burckhardt P., et al. Current use of bisphosphonates in oncology. International Bone and Cancer Study Group. J. Clin. Oncol. 16:1998;3890-3899
14. Cascinu S., Graziano F., Alessandroni P., et al. Different doses of pamidronate in patients with painful osteolytic bone metastases. Support Care Cancer. 6:1998;139-143
15. Koerberle D., Bacchus L., Thuerlimann B., Senn H.J. Pamidronate treatment in patients with malignant osteolytic bone disease and pain a prospective randomised double-blind trial. Support Care Cancer. 7:1999;21-27
16. Conte P.F., Latreille J., Mauriac L., et al. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate results from a multinational randomised controlled trial. J. Clin. Oncol. 14:1996;2552-2559
17. Hortobagyi G.N., Theriault R.L., Lipton A. for the Protocol 19 Aredia Breast Cancer Study Group. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. J. Clin. Oncol. 16:1998;2038-2044
18. Rosen L.S., Gordon D., Kaminski M., et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma a phase III, double-blind, comparative trial. Cancer J. 7:2001;377-387
19. Body J.J., Diel I.J., Lichinitser M.R., et al. Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases. Ann. Oncol. 14:2003;1399-1405
20. Body J.J., Diel I., Tripathy D., Bergstrom B. Impact of ibandronate on bone pain in patients with metastatic bone disease from breast cancer. Support Care Cancer. 11:2003;395-396. (abstr. A-34)
21. Mancini I, Dumon JC, Body JJ. Efficacy and safety of ibandronate in the treatment of opioid-resistant bone pain associated with metastatic bone disease: a pilot study. J Clin Oncol, Submitted.
22. Diel I.J. Ibandronate a well-tolerated intravenous and oral treatment for metastatic bone disease. EJC Supplements. 2:(5):2004;. this issue (doi: 10.1016/j.ejcsup.2004.01.004)
23. Jacox A, Carr DB, Payne R, et al. Management of cancer pain. Quick Reference Guide for Clinicians. Clinical Practice Guideline No. 9. AHCPR Publication No. 94-0592. Rockville, MD. Agency for Health Care Policy and Research, US Department of Health and Human Services, Public Health Service, March, 1994.
24. Bruera E., Schoeller T., Wenk R., et al. A prospective multicenter assessment of the Edmonton staging system for cancer pain. J. Pain Symptom Manage. 10:1995;348-355
25. Kaasa T., Loomis J., Gillis K., et al. The Edmonton Functional Assessment Tool preliminary development and evaluation for use in palliative care. J. Pain Symptom Manage. 13:1997;10-19
26. Oken M.M., Creech R.H., Tormey D.C., et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am. J. Clin. Oncol. 5:1993;649-655
27. Ohlmann C., Heidenreich A. Efficacy of ibandronate in the management of painful osseous metastases due to hormone refractory prostate cancer. Support Care Cancer. 11:2003;396. (abstr A-38)
28. Body J.J. Dosing regimens and main adverse events of bisphosphonates. Semin. Oncol. 28:(Supp. 11):2001;49-53
29. Markowitz G.S., Fine P.L., Stack J.I., et al. Toxic acute tubular necrosis following treatment with zoledronic acid (Zometa). Kidney Int. 64:2003;281-289